Methylene blue in chemoradiotherapy-induced oral mucositis: Systematic review and meta-analysis (2026)

Peer-Reviewed Study · Rondelli E; Romiti E; Gavlasova D; Foppiani JA; Choudry U; Cayci C; Raska O; Ali B; Lin SJ · March 30, 2026

Rondelli E et al., 2026-03-30: PRISMA systematic review and random-effects meta-analysis (PROSPERO CRD42024594258) of methylene blue for pain from chemotherapy- and radiotherapy-induced oral mucositis. Six studies with nine treatment groups and 432 patients gave a pooled pain reduction of 4.81 points on a 0-10 scale.

The pooled mean reduction in pain was -4.81 points on a 0-10 scale (95% CI -5.57 to -4.05; P < 0.001).

Rondelli E et al., 2026-03-30: PRISMA systematic review and random-effects meta-analysis (PROSPERO CRD42024594258) of methylene blue for pain from chemotherapy- and radiotherapy-induced oral mucositis. Six studies with nine treatment groups and 432 patients gave a pooled pain reduction of 4.81 points on a 0-10 scale. Study type: systematic review and meta-analysis of studies in cancer patients with treatment-induced oral mucositis. N=6 studies, 9 treatment groups, 432 patients, from 137 screened records; search to September 2024 across five databases. Countries: not stated in abstract (contributing studies international). Dose/route: methylene blue oral rinse (7 groups) or methylene blue plus laser therapy (2 groups); concentrations per included studies. Comparator: conventional therapy. Result: pooled pain reduction -4.81 points (95% CI -5.57 to -4.05); oral rinse alone -5.01 vs combination -3.80, no significant difference (P=0.30); heterogeneity by I2. Funder/conflicts: not stated in abstract. Authors call for larger randomized trials. This is symptom control, not anti-tumour activity. Study type: review.